Edaravone Suppresses Reperfusion Injury following Leg Ischemia in Rats: A Transmission Electron Microscopic Study

Abstract

It is well known that free radicals cause reperfusion injury following leg ischemia. We showed that the free radical scavenger, edaravone (Radicut, Mitsubishi Tanabe Pharma Co., Osaka, Japan), might suppress reperfusion injury in rat. In this study, we used transmission electron microscope (TEM) to investigate how edaravone suppresses reperfusion injury by focusing on glycogen granules in the lower extremity muscles. Male Lewis rats (582 ± 35 g) were intraperitoneally injected with edaravone (3.0 mg/kg, edaravone group, n = 5) or the same dose of saline (control group, n = 5). The rat reperfusion injury models were induced by clamping the bilateral common femoral arteries for 5 hours and then declamping. The muscles were harvested at 5 hours after the start of reperfusion. Under a TEM (JEM-1220, Nippon Denshi Co., Tokyo, Japan), we counted the number of glycogen granules at ×50,000 magnification on each five different fields. The TEM sections from the control group showed a marked loss of glycogen granules and swollen mitochondria. In contrast, the TEM sections from the edaravone group showed numerous glycogen granules and normal mitochondria. The mean density of glycogen granules in the edaravone group was significantly higher than that in the control group (88.5 ± 5.3 vs. 16.4 ± 3.1 particles/µm², p < 0.001). Our TEM results confirmed that edaravone suppresses reperfusion injury following leg ischemia by maintaining the glycogen granules in muscles.

Keywords

reperfusion injury - free radical - edaravone

Note

This study was presented at Vascular Annual Meeting, Chicago in June, 2011.

• References

• 1 Haimovici H. Arterial embolism with acute massive ischemic myopathy and myoglobinuria: evaluation of a hitherto unreported syndrome with report of two cases. Surgery 1960; 47: 739-747
• 2 Haimovici H. Metabolic complications of acute arterial occlusions and skeletal muscle ischemia: Myonephropathic-metabolic syndrome. In: Haimovici H, , ed. Haimovici's Vascular Surgery, 4th ed. Blackwell Science Inc.: Malden, Massachusetts; 1996: 509-530
• 3 Watanabe T, Morita I, Nishi H, Murota S. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988; 33 (1) 81-87
• 4 Yamamura M, Miyamoto Y, Mitsuno M , et al. Suppression of rat lower extremity postoperative reperfusion injury with edaravone. Int J Angiol 2006; 15 (1) 34-36
• 5 Yamamura M, Miyamoto Y, Mitsuno M , et al. Edaravone suppresses postoperative reperfusion injury in rat lower extremity: An immunohistological study. Int J Angiol 2007; 16 (1) 17-19
• 6 Yamamura M, Miyamoto Y, Mitsuno M , et al. Edaravone reduces mitochondrial damage due to reperfusion injury following leg ischemia in rats. Int J Angiol 2010; 19 (4) e129-e131
• 7 Chiba K, Makuuchi H, Murakami H , et al. Effects of edaravone on prevention of paraplegia caused by ischemic spinal cord. Jpn J Cardiovasc Surg 2008; 37 (2) 82-90 (Abst in English)
• 8 Kitanaka Y, Makuuchi H, Murakami H , et al. Effects of edaravone on cerebral protection during aortic arch surgery. Jpn J Cardiovasc Surg 2011; 40 (2) 48-53 (Abst in English)
• 9 Uchida HA, Takatsuka T, Shikata K , et al. Edaravone attenuate angiotensin II-induced abdominal aortic aneurysms in apolipoprotein E-deficient mice. Arteriosclerosis Thrombosis and Vascular Biology 2011 Scientific Sessions . Program Abstr 2011; 58